First Line Treatment for Hidradenitis Suppurativa (HS)
The first line treatment for hidradenitis suppurativa depends on disease severity, with topical clindamycin 1% twice daily for 3 months recommended for mild disease (Hurley stage I/mild II) and oral tetracyclines for at least 12 weeks for more widespread disease (moderate HS-PGA or Hurley I/mild II). 1, 2
Treatment Algorithm Based on Disease Severity
Mild HS (Hurley Stage I or mild II, localized disease)
First line: Topical clindamycin 1% solution
If inadequate response after 3 months:
- Progress to systemic antibiotics (see moderate HS treatment)
Moderate HS (more widespread Hurley I/mild II or moderate HS-PGA)
First line: Oral tetracyclines
If unresponsive to tetracyclines:
- Combination therapy: Clindamycin 300 mg twice daily + Rifampicin 300 mg twice daily for 10-12 weeks 2
Severe HS (Hurley II/III or moderate-to-severe disease)
- If unresponsive to conventional systemic therapy:
Important Clinical Considerations
Disease Assessment
- Use validated instruments to measure treatment response:
Lifestyle Modifications
- Weight management referral where appropriate 2
- Smoking cessation referral where appropriate 2
- These modifications can significantly impact disease course 5
Comorbidity Screening
- Screen for depression, anxiety, cardiovascular risk factors
- Monitor for inflammatory bowel disease if GI symptoms present 2
Pitfalls and Caveats
Antibiotic Resistance:
Treatment Failure:
- Recurrence rates are high after discontinuation of antibiotics 7
- Early escalation to more definitive therapy may be necessary in non-responders
Avoid in HS Treatment:
Surgical Considerations:
Early intervention with appropriate therapy based on disease severity is crucial to prevent irreversible skin damage and improve quality of life in patients with HS 8.